Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Pulse Biosciences ( (PLSE) ) is now available.
On April 8, 2026, Pulse Biosciences appointed medical technology veteran Liane R. Teplitsky as Chief Operating Officer and expanded the role of Chief Medical Officer Dr. David Kenigsberg, moves the company says are intended to accelerate development and future commercialization of its nPulse Cardiac Catheter Ablation System for atrial fibrillation. As COO, Teplitsky will oversee clinical, regulatory, quality and commercial functions, while her compensation package – including substantial stock options and restricted stock units tied to ambitious market capitalization and GAAP product revenue milestones – aligns her incentives with long-term growth and signals management’s confidence in Pulse Biosciences’ ability to scale its pulsed field ablation franchise.
The company also disclosed inducement equity awards to Teplitsky and to two additional new hires, further reinforcing a strategy of using performance-based equity to attract and retain talent critical to executing its clinical and regulatory roadmap. Kenigsberg’s expanded leadership role, while he maintains an active clinical practice, is expected to bolster the company’s pivotal IDE study of the nPulse Cardiac Catheter System and deepen its clinical expertise in electrophysiology and pulsed field ablation as it advances toward potential commercialization.
The most recent analyst rating on (PLSE) stock is a Hold with a $23.50 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
The score is primarily held back by weak financial performance—minimal revenue, large losses, and heavy cash burn—despite a currently supportive balance sheet. Technicals are a clear positive with strong trend/momentum signals, while valuation remains unattractive due to ongoing unprofitability. Clinical and regulatory milestones from the earnings call and recent announcements improve the outlook, but funding and commercialization risks still weigh on the overall score.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. is a bioelectric medicine company developing its proprietary nPulse nanosecond pulsed field ablation technology, which delivers non-thermal electrical pulses to clear targeted cells while sparing surrounding tissue. The company is focused on advancing this platform for the treatment of atrial fibrillation and select additional markets where it believes the technology could significantly improve healthcare outcomes.
Average Trading Volume: 348,135
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.3B
Find detailed analytics on PLSE stock on TipRanks’ Stock Analysis page.